NCT00937157View on ClinicalTrials.gov

Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

July 31, 2010

Study Completion Date

April 30, 2011

Conditions
Multiple Sclerosis
Interventions
DRUG

Copaxone

12 MS patients will be enrolled on GA (Copaxone®) monotherapy (20mg/day sc). Initial intravenous steroid treatment will be given on day 0. 1.5T and 3T scans will be obtained and according to the following schedule: 1 gm Solumedrol i.v. daily for three days. Intravenous steroids will be also allowed for treatment of MS attacks according to the following schedule: 1 gm Solumedrol i.v. daily for three days.

Trial Locations (1)

14203

Jacobs Neurological Institute, Buffalo

All Listed Sponsors
collaborator

Teva Neuroscience, Inc.

INDUSTRY

lead

University at Buffalo

OTHER

NCT00937157 - Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA) | Biotech Hunter | Biotech Hunter